Life Science Investing HCW Biologics' Scientists to Present Three Posters During the 40th Annual Meeting of the Society for Immunotherapy of Cancer
Life Science Investing HCW Biologics Inc. Participates in Virtual Investor "What This Means" Segment About its Proprietary T-Cell Engager Program
Life Science Investing HCW Biologics, a Shareholder of Wugen, Congratulates Wugen on Its Recent Successful Equity Financing
Life Science Investing Anti-Aging Biotech Surges as $101M Competition Ignites Global Race Against Aging Demographics
Life Science Investing HCW Biologics Designates One of Its Proprietary TRBC-Pembrolizumab-Based Immune Checkpoint Inhibitors as its Franchise Immunotherapeutic for Internal Clinical Development
Life Science Investing HCW Biologics Reports Positive Results from Non-Human Primate Study for Its Proprietary Second-Generation T-Cell Engager Program
Life Science Investing HCW Biologics to Showcase its Novel Second-Generation Immune Checkpoint Inhibitor Identified as a Potential Gateway to a Multi-Billion Dollar Market
NextSource Materials Announces Upsizing of Funding Facility from Vision Blue Resources to Advance UAE Anode Facility Development
